Impaired mitochondrial function results in increased tissue transglutaminase activity in situ.
about
Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's diseaseProtein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional proteinDiurnal changes in mitochondrial function reveal daily optimization of light and dark respiratory metabolism in ArabidopsisInhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.Keratin 8 phosphorylation regulates its transamidation and hepatocyte Mallory-Denk body formation.Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.Effects of Fructus Piperis Longi extract on fibrotic liver of gamma-irradiated rats.Monitoring of transglutaminase 2 under different oxidative stress conditions.Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells.Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress.Tissue transgluaminase 2 expression in meningiomas.Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin.Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner.Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders.Differential incorporation of biotinylated polyamines by transglutaminase 2.Glutamate-evoked redox state alterations are involved in tissue transglutaminase upregulation in primary astrocyte cultures.
P2860
Q24618141-FEBCEF55-8DDB-415C-B102-E9FC922A6F7FQ28247511-A8F33DC0-3A4D-41D2-B537-4E89A7EEFF4AQ34193631-618B92CF-0930-4727-8CF5-2094148B8770Q34743269-2434FF8D-130A-41B1-82C7-447F74CB4510Q34763209-3E023EC5-692C-47B3-9118-5178C9A983D9Q34994779-102FBF14-45F1-40A8-B85C-CC82F73770E7Q35987918-F26BF8BA-5CBC-44F6-99E2-F9B80180D98CQ37001587-C85B4670-D41B-4AF1-B962-B0E73B931716Q37132057-B98451D8-74C9-4800-ACE9-94AD0735D800Q37909103-E0CB9C04-2B7B-4B9A-9E0C-2FB1EED2E281Q40290417-07F661A2-3E32-43F1-8568-3E43C6A44F65Q40725013-3B525E41-A6DD-4D6E-A83C-FE69AAB19BE7Q41834313-D16201A4-EF54-4C9D-B6C0-28124682FCD1Q42510495-CDA69907-483A-4E4C-9166-8BE496EA79D1Q44028749-44D9175B-307C-4EBA-A114-6DE86DD61AE1Q44233701-5D5BCC8C-6A6E-40AD-9B0F-0522AF49C9D0Q44277951-76098A3D-EF96-498F-92B8-421920E87DA2Q45175163-2979E9AF-C8EB-44C7-87D3-CF67E6C88F76
P2860
Impaired mitochondrial function results in increased tissue transglutaminase activity in situ.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Impaired mitochondrial functio ...... sglutaminase activity in situ.
@en
Impaired mitochondrial functio ...... sglutaminase activity in situ.
@nl
type
label
Impaired mitochondrial functio ...... sglutaminase activity in situ.
@en
Impaired mitochondrial functio ...... sglutaminase activity in situ.
@nl
prefLabel
Impaired mitochondrial functio ...... sglutaminase activity in situ.
@en
Impaired mitochondrial functio ...... sglutaminase activity in situ.
@nl
P2093
P2860
P1476
Impaired mitochondrial functio ...... sglutaminase activity in situ.
@en
P2093
P2860
P304
P356
10.1046/J.1471-4159.2000.0751951.X
P407
P577
2000-11-01T00:00:00Z